Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
13 août 2024 08h00 HE
|
Autonomix Medical, Inc.
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the source Positive 7-day topline results from first...
Autonomix Completes Licensing Transaction for FDA-Cleared Ablation Technology
24 juil. 2024 08h00 HE
|
Autonomix Medical, Inc.
RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further reinforces Autonomix’s FDA regulatory...
Autonomix Enters into Definitive Agreement to License Intellectual Property for FDA-Cleared Ablation Technology from RF Innovations, Inc.
15 juil. 2024 08h00 HE
|
Autonomix Medical, Inc.
RF Innovations’ Apex 6 Generator aligns with specifications required for Autonomix’s ablation system and facilitates ongoing development Transaction further reinforces Autonomix’s FDA...
Autonomix Medical, Inc. (NASDAQ: AMIX) Announces Launch of CEO Corner Platform
11 juil. 2024 09h00 HE
|
Autonomix Medical, Inc.
CEO Corner segments to include additional discussion related to press releases, events, corporate updates and pipeline progress Access the Autonomix CEO Corner Here! THE WOODLANDS, TX, July 11,...
Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment
03 juil. 2024 09h00 HE
|
Autonomix Medical, Inc.
Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses preliminary positive results from the first five “lead-in” patients in the Company’s ongoing human clinical trial THE...
Autonomix Enhances Executive Leadership Team with Appointment of Proven Medical Technology Leader, Brad Hauser, as President and Chief Executive Officer
17 juin 2024 16h05 HE
|
Autonomix Medical, Inc.
Former President and Chief Executive Officer, Lori Bisson, appointed as Executive Vice Chairman THE WOODLANDS, TX, June 17, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX)...
Autonomix to Announce Preliminary Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial on June 18, 2024
10 juin 2024 08h00 HE
|
Autonomix Medical, Inc.
Management to host live webcast to discuss results on Tuesday, June 18th at 8:30 a.m. ET THE WOODLANDS, TX, June 10, 2024 (GLOBE NEWSWIRE) -- – Autonomix Medical, Inc. (NASDAQ: AMIX)...
Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update
31 mai 2024 08h05 HE
|
Autonomix Medical, Inc.
Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued progress in first study ever to evaluate...
Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer
23 mai 2024 09h15 HE
|
Autonomix Medical, Inc.
Results from the preclinical study demonstrated statistically significant reduction of metastases and statistically significant reduction in tumor mass Lori Bisson, Chief Executive Officer...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
14 mai 2024 16h15 HE
|
Autonomix Medical, Inc.
Live webcast on Thursday, May 16th at 4:00 PM ET THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company...